Dendreon Plunges on Provenge Forecast Withdrawal

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

Aug. 4 (Bloomberg) -- Dendreon Corp., maker of the prostate-cancer drug Provenge, fell the most in two years after the company withdrew its 2011 revenue estimate and said sales of the medicine didn’t meet projections. Shannon Pettypiece reports on Bloomberg Television's "In the Loop." (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change